Deupirfenidone Receives Orphan Drug Status for IPF – FDA & EC Approval

The U.S. Food and Drug Administration (FDA) and the European Commission have granted Orphan Drug Designation to deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF), a serious and currently incurable lung disease. This designation, announced by PureTech Health plc on February 19, 2026, recognizes the urgent need for new therapies for this rare condition and provides incentives for its development. PureTech, the biotherapeutics company advancing deupirfenidone through its Founded Entity Celea Therapeutics, highlighted the significance of this dual designation.

Understanding Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized by scarring of the lungs, making it difficult to breathe. “Idiopathic” means the cause is unknown. The scarring thickens and stiffens lung tissue, reducing lung capacity and leading to shortness of breath, a persistent dry cough, fatigue, and eventually respiratory failure. IPF affects fewer than 200,000 people in the United States and fewer than 5 in 10,000 individuals in the European Union, qualifying it as a rare disease – the criteria for Orphan Drug Designation. Currently, We find only three FDA-approved therapies for IPF, but tolerability and efficacy remain significant challenges for many patients. As reported by AJMC, deupirfenidone is a next-generation antifibrotic, meaning it aims to slow down the scarring process in the lungs.

What Does Orphan Drug Designation Mean?

Orphan Drug Designation is a status granted by regulatory agencies like the FDA and the European Commission to encourage the development of medications for rare diseases. Due to the fact that the potential market for these drugs is smaller, pharmaceutical companies may be less inclined to invest in their development without additional incentives. The designation provides several benefits, including market exclusivity – a period during which the drug can be sold without competition from similar medications – as well as tax credits, waived fees, and assistance with clinical trial design. These incentives aim to offset the financial risks associated with developing treatments for rare conditions.

Deupirfenidone: A Next-Generation Approach

Deupirfenidone is a deuterated form of pirfenidone, one of the existing FDA-approved treatments for IPF. Deuteration is a process where hydrogen atoms in a molecule are replaced with deuterium, a heavier isotope of hydrogen. This modification can alter the drug’s metabolism, potentially improving its efficacy and reducing side effects. The goal with deupirfenidone is to maintain the therapeutic benefits of pirfenidone while addressing some of its limitations, particularly regarding tolerability. Robert Lyne, Chief Executive Officer of PureTech Health, emphasized that a significant proportion of IPF patients currently do not receive treatment with existing therapies due to these tolerability issues and modest efficacy.

Beyond Deupirfenidone: Other Approaches to IPF

While deupirfenidone represents a promising new avenue for IPF treatment, other therapies are similarly under investigation. Endeavor BioMedicines, for example, has also received Orphan Drug Designation for taladegib (ENV-101) for IPF. Taladegib is a Hedgehog pathway inhibitor currently being studied in a Phase 2b clinical trial (WHISTLE-PF) and aims to reverse the course of the disease by targeting different mechanisms involved in lung fibrosis. The WHISTLE-PF trial is expected to complete enrollment in 2026. These parallel efforts highlight the ongoing commitment to finding more effective treatments for IPF.

What’s Next for Deupirfenidone and IPF Research?

With Orphan Drug Designation secured, Celea Therapeutics will continue to advance the development of deupirfenidone. This includes conducting further clinical trials to evaluate its safety and efficacy in patients with IPF. The company will also work closely with regulatory authorities to prepare for potential market approval. The process of drug development is lengthy and complex, involving multiple phases of clinical trials to demonstrate both safety and effectiveness. The FDA and European Commission will carefully review the data from these trials before making a decision on whether to approve deupirfenidone for widespread employ. Ongoing research will also focus on identifying biomarkers that can help predict which patients are most likely to respond to treatment and on developing personalized therapies tailored to individual patient needs. Further investigation into the underlying causes of IPF remains a critical area of focus, with the hope of eventually finding a cure for this devastating disease.